HMOs Gaining Increasing Control Over US Health Care

26 February 1996

A strong future for self-medication was predicted by Russell Coile, president of the Health Forecasting Group, speaking at a recent Nonprescription Drug Manufacturers Association marketing seminar in New York. He also noted that the cost-driven growth of managed care will continue, giving health maintenance organizations increasing control over US health care.

HMOs now serve more than 50 million Americans, he said, predicting that federal and state governments (ie through Medicare and Medicaid) will follow the lead of the private sector toward increased managed care. Congressional efforts to cut Medicare will encourage seniors to join Medicare HMOs, he added.

But They Are Being Challenged Nevertheless, Mr Coile cautioned, the power of the HMO industry is not going unchallenged. Criticism of managed care is mounting, he said; health care providers, employers and the media are challenging premiums, HMO profits, denial of treatment and rationing. The results, he claimed, will include employer and business coalitions demanding lower prices from HMOs and government regulations, such as minimum 48-hour hospital stays for newborns and mothers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight